News

DTU Director discusses EXSCEL

18-Jan-2018
The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) is a trial that assessed the long-term cardiovascular safety and efficacy of once-weekly exenatide, administered in patients with type 2 diabetes who had a wide range of cardiovascular risk. In this video, Professor Rury Holman shares his insights into the trial results.